2022年8月9日 · Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a significant concern and generally portends a poor pr …

2024年12月24日 · Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis.

Allogeneic hematopoietic cell transplant (allo-HCT) for eligible patients with acute myeloid leukemia (AML) in first complete remission is a central treatment paradigm to achieve durable remission. However, disease relapse after allo-HCT remains a ...

Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML) represents the only curative option. Progress has been made in the last two decades in the pre-transplant induction therapies, supportive care, ...

2024年1月4日 · Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative strategy for most patients. Therapeutic approaches, including allogeneic HCT, triggered by the presence of measurable residual disease (MRD), have recently evolved to prevent overt hematologic relapse.

2023年1月5日 · Disease relapse is the leading cause of failure for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Maintenance therapy administered after allo-HCT is a promising strategy to reduce the incidence of relapse and enhance the curative potential of …

2021年12月16日 · With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of treatment failure for patients with acute myeloid leukemia (AML). The efficacy of allo-HCT in AML is a consequence of a graft-versus-leukemia (GVL) effect that is mediated by T lymphocytes ...

2024年12月27日 · Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis.

In patients diagnosed with intermediate or high-risk acute myeloid leukemia (AML) allogeneic hematopoietic cell transplantation (allo-HCT) remains in most cases the only curative option. However, despite major improvements in allo-HCT, disease relapse remains the main cause of treatment failure and mortality.

Allogeneic hematopoietic stem-cell transplantation (HCT) is one of the principal curative approaches in the treatment of acute myeloid leukemia (AML); however, relapse post-transplantation remains a catastrophic event with poor prognosis.

2022年6月15日 · Allo-HCT is a key consideration in treating children and adolescents with AML, and for many, HCT offers the best chance at long-term survival. Those with unfavorable-risk features, namely cytomolecular aberrations or suboptimal response to induction therapy, experience the most benefit when undergoing HCT in CR1.

2023年11月11日 · In this review, we summarize different ways of immune escape in AML patients after allo-HCT, separating mechanisms leading to impaired HLA expression from those characterized by aberrant immune checkpoint expression and differential effects leading to a remodeling of the TME.

2025年1月1日 · AML移植后复发. 异基因造血干细胞移植（allo-HCT）是治疗急性髓系白血病（AML）的主要方法之一，但移植后复发仍预后不良， 1 年总生存率（OS）仅为 23%。

eln等风险分层标准通常用于讨论aml预后，并就hct或其他旨在巩固缓解并提供长期生存的诱导后选择提供建议。 这些标准使用细胞遗传学和分子标志物对患者进行风险分层，但多是从接受传统强化疗的年轻患者中得出的。

2025年1月21日 · Allo-HCT is among the principal curative treatment approaches for AML, but the prognosis remains poor for patients who relapse after transplantation. 1 Treatment approaches for post-transplantation relapse are highly individualized and are informed by disease genomics and biology, the clinical status of a patient at relapse, and the interval ...

With advances in allogeneic hematopoietic stem cell transplant (allo-HCT), disease relapse has replaced transplant-related mortality as the primary cause of treatment failure for patients with acute myeloid leukemia (AML).

2017年12月1日 · Increasing numbers of patients are receiving allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML). Scientific and clinical advances in supportive care, donor selection, and conditioning regimens have resulted in lower transplant-related mortality, extension of care to a wider population of patients, and ...

5 天之前 · QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy.We evaluated the impact of allo-HCT performed in first ...

2024年5月29日 · Our study analyzed HCT use in patients with AML from 2004 to 2019 to determine whether the use of HCT has improved in more recent years and identify study subpopulations with an increase in the use of HCT. Methods: Patients with AML from the National Cancer Database were divided into two primary cohorts: patients diagnosed from 2004-2010 and ...

2023年5月22日 · Allogeneic hematopoietic stem cell transplant (HCT) has improved survival for patients with acute myeloid leukemia (AML), especially for those at high risk of relapse. However, relapse remains the leading cause of treatment failure post-HCT, occurring in around 35–45% of patients, and leading to dismal outcomes.